Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study-Reference-Cited by-同舟云学术

Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study

Published:2020-08 Issue: Volume:415 Page:116880
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Bringeland Gerd Haga,Myhr Kjell-Morten,Vedeler Christian Alexander,Gavasso Sonia

Funder

Fritz og Ingrid Nilsens legat

Hanne Linda Nakkestad at the Neurological Research Laboratory at Haukeland University Hospital

SiMOA

Bergen Research Foundation

Haukeland University Hospital

University of Bergen

Centre for Clinical Treatment Research

The Research Council of Norway

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference10 articles.

1. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;N. Engl. J. Med.,2006

2. Monitoring CD49d receptor occupancy: A method to optimize and personalize natalizumab therapy in multiple sclerosis patients;Punet-Ortiz;Cytometry B Clin. Cytom.,2017

3. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab;Gunnarsson;Ann. Neurol.,2011

4. Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle;Ratchford;Int. J. MS Care,2014

5. The natalizumab wearing-off effect: End of natalizumab cycle; recurrence of MS symptoms;van Kempen;Neurology,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial;Journal of the Neurological Sciences;2024-07

2. The patient-reported wearing-off phenomenon with monoclonal antibody treatments for multiple sclerosis;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2024-04

3. Sociodemographic and Clinical Determinants of Fatigue in Multiple Sclerosis;Life;2023-10-29

4. No Increase in Symptoms Toward the End of the Ocrelizumab Infusion Cycle in Patients With Multiple Sclerosis;Neurology Clinical Practice;2023-10

5. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-04